Lexeo Therapeutics (LXEO) CMO Bhalla Narinder Pal Receives Awards

What Happened
Bhalla Narinder Pal, Chief Medical Officer of Lexeo Therapeutics (LXEO), reported two transactions: a cash purchase of 2,714 shares through the company Employee Stock Purchase Plan (ESPP) on 2026-09-14 at $3.58/share (total ≈ $9,713), and a grant of 54,750 derivative awards on 2026-09-24 recorded at $0 (a compensation award, not a market purchase). The derivative grant includes restricted stock units and other awards subject to vesting.

Key Details

• Transaction dates and prices:
  • 2026-09-14: ESPP purchase — 2,714 shares at $3.58 each (≈ $9,713). (Footnote F1: voluntarily reported; exempt under Rule 16b-3(c) and (d).)
  • 2026-09-24: Grant/award — 54,750 derivative shares at $0 (Acquired). (Footnote F2: includes 49,500 Restricted Stock Units.)
  • Footnote F3: part of the award vests 25% on 2027-09-24, then 1/48th monthly thereafter, subject to continued service.
• Shares owned after the reported transactions: not specified in the provided filing.
• Filing date: 2026-09-28. The 9/24 grant was reported within the typical two-business-day window (due 9/28). The 9/14 ESPP purchase was voluntarily reported together and noted as exempt in the filing.
• No indication the derivative awards were sold or cashed out; they are compensation grants subject to vesting.

Context
The $0 price on the 54,750-share item indicates a compensatory grant (RSUs/options) rather than a market purchase; such awards vest over time and are commonly used for retention. The ESPP purchase is a small, routine insider buy funded by payroll or cash contribution. These entries are factual disclosures of acquisitions and grants; they do not, by themselves, indicate immediate selling or investment intent.